NCT06892249

Suitability of Two Flavours of a High-energy, Low-protein Formula (Renalive® LP) in Chronic Kidney Disease Stage 3b-5 Outpatients in Taiwan

Recruiting now NA Last updated 16 March 2026

What this trial tests

NA trial testing Renalive® LP, flavour Vanilla in CKD in 80 participants. Currently enrolling.

Timeline

4 June 2025

Primary endpoint
30 April 2026

30 April 2026

Quick facts

Lead sponsor	Fresenius Kabi Taiwan Ltd.
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	80
Start date	4 June 2025
Primary completion	30 April 2026
Estimated completion	30 April 2026
Sites	3 locations across Taiwan

Drugs / interventions tested

• Renalive® LP, flavour Vanilla
• Renalive® LP, flavour Cappuccino

Conditions studied

• CKD — all drugs for CKD →
• Low Protein Dietary Intake — all drugs for Low Protein Dietary Intake →
• Malnutrition (Calorie) — all drugs for Malnutrition (Calorie) →

Sponsor

Fresenius Kabi Taiwan Ltd. — full company profile →

Who can join

Adults 18 to 80, any sex, with CKD or Low Protein Dietary Intake. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Purpose of study To evaluate suitability of two flavours of a high energy low protein formula (Renalive® LP) as oral nutritional supplement and meal replacement in chronic kidney disease stage 3b-5 outpatients Inclusion criteria (1) Diagnosed with chronic kidney disease stage 3b-5 (with history of eGFR\<45 mL/min/1.73 m2) (2) Age: 18-80 years (3) Outpatients with instruction to keep a low protein diet (0.55-0.8 g protein /kg actual body weight/ day) in the last 3 months as evaluated by the Investigator.

(4) Written Informed Consent from patient. Exclusion criteria

1. Has received dialysis or are expected to start dialysis within the next 3 months.
2. Patients awaiting kidney transplant.
3. Body mass index (BMI) \<18 kg/m2 or BMI \>30 kg/m2
4. Malnourished patients with albumin \<3 g/dL in need of extra calories and nutrients
5. Patients receiving or having received oral/enteral/parenteral nutrition supplementation for special medical purpose in the last 28 days
6. Severe liver disease, malignant neoplastic disease, current significant infectious disease (apart from flu, cold, Hepatitis C virus (HCV) carrier, Hepatitis B virus (HBV) carrier, skin infection) deemed unsuitable for entering the trial as evaluated by the Investigator
7. Existing gastrointestinal disease or pathological findings that cannot tolerate enteral nutrition or render enteral nutrition unfeasible, such as shock, acute upper gastrointestinal bleeding, intestinal sluggishness, intestinal obstruction, or malabsorption, such as inflammatory bowel disease, pancreatic disease, or gastrointestinal surgery
8. Severe impairment of gastrointestinal function, i.e. severe constipation or acute diarrhoea (≥3 loose or watery stools a day)
9. Swallowing difficulty or high risk of aspiration
10. Central nervous system and/or certain psychiatric disorders where the patient is considered as not yet clinically stable and/or not suitable to participate in this study by the Investigator
11. Known allergic reaction or intolerance to any ingredient of the intervention formula.
12. Surgery or hospitalization scheduled during the trial
13. Suspected drug abuse
14. Unable to follow study instructions or keep a dietary diary
15. Pregnant or lactating women
16. Participation in other clinical trials using investigational drugs within 30 days before the start of the trial or during the trial.

Primary Endpoint

(1) Change in body weight from Baseline to end of treatment at Week 4 (Week 4 - Baseline) Secondary Endpoints

1. Daily dietary intake of energy, protein, sodium, potassium, magnesium, phosphorus, and calcium at Baseline, Week 2 and 4 based on a 3-Day Dietary Record
2. Change of nutritional status using body weight, BMI, and body composition as indicators:

* Change in body weight from Baseline to Week 2
* Change in BMI from Baseline to Week 2 and week 4
* Change in body composition from Baseline to Week 4 using bioelectrical impedance assessment
3. Change of the physical performance using hand grip strength as an indicator from Baseline to Week 4
4. Change of renal function:

* Change in estimated glomerular filtration rate (eGFR) (Chronic Kidney Disease Epidemiology Collaboration \[CKD-EPI\]) from Baseline to Week 4
* Change in blood urea nitrogen and serum creatinine from Baseline to Week 2 and 4
5. Serum albumin and pre-albumin at Baseline and Week 4
6. Blood electrolytes (sodium, potassium, phosphorus, calcium, magnesium) at Baseline, Week 2 and 4
7. Serum C-reactive protein (CRP) at Baseline, Week 2 and 4
8. Compliance rate (%) to Renalive® LP

Publications & conference data

No peer-reviewed publications indexed yet for this trial.